cardiovascular cannabidiol - PMC

Jairo Vinícius Pinto, Gayatri Saraf, Christian Frysch, Daniel Vigo, Kamyar Keramatian, Trisha Chakrabarty, Raymond W. Lam, Márcia Kauer-Sant’Anna, Lakshmi N. Yatham

Can J Psychiatry. 2020 Apr; 65(4): 213–227. doi: 10.1177/0706743719895195

PMCID:: PMC7385425

Article PubReader PDF–410K Cite

Select item 76996137.

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

María S. García-Gutiérrez, Francisco Navarrete, Ani Gasparyan, Amaya Austrich-Olivares, Francisco Sala, Jorge Manzanares

Biomolecules. 2020 Nov; 10(11): 1575. Published online 2020 Nov 19. doi: 10.3390/biom10111575

PMCID:: PMC7699613

Article PubReader PDF–807K Cite

Select item 76412678.

Therapeutic Applications of Cannabinoids in Cardiomyopathy and Heart Failure

J. A. Garza-Cervantes, M. Ramos-González, O. Lozano, C. Jerjes-Sánchez, G. García-Rivas

Oxid Med Cell Longev. 2020; 2020: 4587024. Published online 2020 Oct 27. doi: 10.1155/2020/4587024

PMCID:: PMC7641267

Article PubReader PDF–982K Cite

Select item 97164909.

Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool

Caroline MB Kwee, Joop MA van Gerven, Fleur LP Bongaerts, Danielle C Cath, Gabriël Jacobs, Johanna MP Baas, Lucianne Groenink

J Psychopharmacol. 2022 Dec; 36(12): 1299–1314. Published online 2022 Oct 14. doi: 10.1177/02698811221124792

PMCID:: PMC9716490

Article PubReader PDF–1.4M Cite

Select item 717043410.

Vasodilatory effects of cannabidiol in human pulmonary and rat small mesenteric arteries: modification by hypertension and the potential pharmacological opportunities

Marta Baranowska-Kuczko, Hanna Kozłowska, Monika Kloza, Olga Sadowska, Mirosław Kozłowski, Magdalena Kusaczuk, Irena Kasacka, Barbara Malinowska

J Hypertens. 2020 May; 38(5): 896–911. Published online 2019 Dec 2. doi: 10.1097/HJH.0000000000002333

PMCID:: PMC7170434

Article PubReader PDF–1.2M Cite

Select item 725611811.

The effects of acute and sustained cannabidiol dosing for seven days on the haemodynamics in healthy men: A randomised controlled trial

Salahaden R. Sultan, Saoirse E. O'Sullivan, Timothy J. England

Br J Clin Pharmacol. 2020 Jun; 86(6): 1125–1138. Published online 2020 Mar 3. doi: 10.1111/bcp.14225

PMCID:: PMC7256118

Article PubReader PDF–1.4M Cite

Select item 724693612.

Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals?

Vicente Martínez, Amaia Iriondo De-Hond, Francesca Borrelli, Raffaele Capasso, María Dolores del Castillo, Raquel Abalo

Int J Mol Sci. 2020 May; 21(9): 3067. Published online 2020 Apr 26. doi: 10.3390/ijms21093067

PMCID:: PMC7246936

Article PubReader PDF–2.7M Cite

Select item 779692413.

Cannabidiol: Pharmacology and Therapeutic Targets

Stevie C. Britch, Shanna Babalonis, Sharon L. Walsh

Psychopharmacology (Berl) Author manuscript; available in PMC 2022 Jan 1.

Published in final edited form as: Psychopharmacology (Berl). 2021 Jan; 238(1): 9–28. Published online 2020 Nov 21. doi: 10.1007/s00213-020-05712-8

PMCID:: PMC7796924

Article PubReader PDF–187K Cite

Select item 707294114.

Chronic Cannabidiol Administration Fails to Diminish Blood Pressure in Rats with Primary and Secondary Hypertension Despite Its Effects on Cardiac and Plasma Endocannabinoid System, Oxidative Stress and Lipid Metabolism

Patryk Remiszewski, Iwona Jarocka-Karpowicz, Michał Biernacki, Anna Jastrząb, Eberhard Schlicker, Marek Toczek, Ewa Harasim-Symbor, Anna Pędzińska-Betiuk, Barbara Malinowska

Int J Mol Sci. 2020 Feb; 21(4): 1295. Published online 2020 Feb 14. doi: 10.3390/ijms21041295

PMCID:: PMC7072941

Article PubReader PDF–5.1M Cite

Select item 915724415.

Cannabidiol and substance use disorder: dream or reality

Saeideh Karimi-Haghighi, Yasaman Razavi, Daniela Iezzi, Andrew F. Scheyer, Olivier Manzoni, Abbas Haghparast

Neuropharmacology. Author manuscript; available in PMC 2023 Apr 1.

Published in final edited form as: Neuropharmacology. 2022 Apr 1; 207: 108948. Published online 2022 Jan 13. doi: 10.1016/j.neuropharm.2022.108948

PMCID:: PMC9157244

Article PubReader PDF–528K Cite

Select item 1004885716.

THC and CBD: Villain versus Hero? Insights into Adolescent Exposure

Nicholas Pintori, Francesca Caria, Maria Antonietta De Luca, Cristina Miliano

Int J Mol Sci. 2023 Mar; 24(6): 5251. Published online 2023 Mar 9. doi: 10.3390/ijms24065251

PMCID:: PMC10048857

Article PubReader PDF–2.3M Cite

Select item 705283417.

Cannabidiol Adverse Effects and Toxicity

Marilyn A. Huestis, Renata Solimini, Simona Pichini, Roberta Pacifici, Jeremy Carlier, Francesco Paolo Busardò

Curr Neuropharmacol. 2019 Oct; 17(10): 974–989. Published online 2019 Oct. doi: 10.2174/1570159X17666190603171901

PMCID:: PMC7052834

Article PubReader PDF–548K Cite

Select item 616164418.

Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age

José A. Crippa, Francisco S. Guimarães, Alline C. Campos, Antonio W. Zuardi

Front Immunol. 2018; 9: 2009. Published online 2018 Sep 21. doi: 10.3389/fimmu.2018.02009

PMCID:: PMC6161644

Article PubReader PDF–1.1M Cite

Select item 752808119.

The electrophysiological effect of cannabidiol on hERG current and in guinea-pig and rabbit cardiac preparations

Péter Orvos, Bence Pászti, Leila Topal, Péter Gazdag, János Prorok, Alexandra Polyák, Tivadar Kiss, Edit Tóth-Molnár, Boglárka Csupor-Löffler, Ákos Bajtel, András Varró, Judit Hohmann, László Virág, Dezső Csupor

Sci Rep. 2020; 10: 16079. Published online 2020 Sep 30. doi: 10.1038/s41598-020-73165-2

PMCID:: PMC7528081

Article PubReader PDF–2.9M Cite

Select item 809501120.

Anti‐seizure medications for Lennox‐Gastaut syndrome

Cochrane Database Syst Rev. 2021; 2021(4): CD003277. Published online 2021 Apr 7. doi: 10.1002/14651858.CD003277.pub4

PMCID:: PMC8095011

Article PubReader PDF–1.2M Cite

<< First< Prev

Page of 185

Next >Last >>

Supplemental Content

Filter your results:

Manage Filters

PMC Images search for cardiovascular cannabidiol

Figure 5

Effects of cannabidiol (CBD) on the cardiovascular system under physiological and pathological conditions [,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,]. Abbreviations: BP: blood pressure, HR: heart rate; this figure was prepared using a template on the Servier Medical Art website.

The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease

Int J Mol Sci. 2020 Sep;21(18):6740.
Figure 8

Possible mechanisms involved in the cardiovascular effects of cannabidiol (CBD) in normotensive Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats.

Cannabidiol Affects the Bezold-Jarisch Reflex via TRPV1 and 5-HT3 Receptors and Has Peripheral Sympathomimetic Effects in Spontaneously Hypertensive and Normotensive Rats

Front Pharmacol. 2019;10:500.
Figure 3

Metabolism of cannabidiol [,,,,,,,,]. Abbreviations: 7-COOH-, 7-OH-CBD:7-Carboxy-, 7-hydroxycannabidiol; CBD: Cannabidiol; CYP: Cytochrome P450; p.o.: Per os, orally; s.c.: Subcutaneously; THC: Δ⁹-Tetrahydrocannabinol; UGT: UDP-Glucuronosyltransferase.

The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease

Int J Mol Sci. 2020 Sep;21(18):6740.
Figure 4

Mean arterial pressure (MAP), pulsatile arterial pressure (PAP) and heart rate (HR) individual recordings showing the cardiovascular changes evoked by acute restraint in animals treated with vehicle (control, Tween 80 2%-saline), cannabidiol (CBD) or cannabidiol after WAY100635 (WAY+CBD). The restraint period started at time 0.

5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats

Br J Pharmacol. 2009 Jan;156(1):181-188.